Silexion receives Nasdaq bid price deficiency notice; reverse split set for July 29

Silexion Therapeutics Corp

On July 18, 2025, Nasdaq notified Silexion that its ordinary shares' closing bid price was below $1.00 for 30 consecutive days.
Bid price deficiency will be considered by Nasdaq hearings panel in continued listing decision.
Shareholder-approved 1-for-15 reverse split effective after market close July 28; trading begins split-adjusted July 29.
Company must also meet $2.5M minimum shareholders' equity by September 19, 2025 to maintain listing.
Current trading of shares (SLXN) and warrants (SLXNW) unaffected at this time.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.